|
1
|
Vincent A, Herman J, Schulick R, Hruban RH
and Goggins M: Pancreatic cancer. Lancet. 378:607–620. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Morganti AG, Massaccesi M, La Torre G,
Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M,
Macchia G, et al: A systematic review of resectability and survival
after concurrent chemoradiation in primarily unresectable
pancreatic cancer. Ann Surg Oncol. 17:194–205. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Liao WC, Chien KL, Lin YL, Wu MS, Lin JT,
Wang HP and Tu YK: Adjuvant treatments for resected pancreatic
adenocarcinoma: A systematic review and network meta-analysis.
Lancet Oncol. 14:1095–1103. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gaida MM, Welsch T and Herpel E: MHC class
II expression in pancreatic tumors: A link to intratumoral
inflammation. Virchows Arch. 460:47–60. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sartoris S, Valle MT, Barbaro AL, Tosi G,
Cestari T, D'Agostino A, Megiovanni AM, Manca F and Accolla RS: HLA
class II expression in uninduciblehepatocarcinoma cells after
transfection of AIR-1 gene product CIITA: Acquisition of antigen
processing and presentation capacity. J Immunol. 161:814–820.
1998.PubMed/NCBI
|
|
7
|
van Eggermond MC, Tezcan I, Heemskerk MH
and van den Elsen PJ: Transcriptional silencing of RFXAP in MHC
class II-deficiency. Mol Immunol. 45:2920–2928. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ding G, Zhou L, Qian Y, Fu M, Chen J, Chen
J, Xiang J, Wu Z, Jiang G and Cao L: Pancreatic cancer-derived
exosomes transfer miRNAs to dendritic cells and inhibit RFXAP
expression via miR-212-3p. Oncotarget. 6:29877–29888. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Blanck G: Components of the IFN-gamma
signaling pathway in tumorigenesis. Arch Immunol Ther Exp.
50:151–158. 2002.
|
|
10
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Einhorn S and Strander H: Interferon
treatment of human malignancies-a short review. Med Oncol Tumor
Pharmacother. 10:25–29. 1993.PubMed/NCBI
|
|
12
|
Vihinen P, Tervahartiala T, Sorsa T,
Hansson J, Bastholt L, Aamdal S, Stierner U, Pyrhönen S, Syrjänen
K, Lundin J and Hernberg M: Benefit of adjuvant interferon alfa-2b
(IFN-α) therapy in melanoma patients with high serum MMP-8 levels.
Cancer Immunol Immunother. 64:173–180. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Boehm U, Klamp T, Groot M and Howard JC:
Cellular responses to interferon-gamma. Annu Rev Immunol.
15:749–795. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Endou M, Mizuno M, Nagata T, Tsukada K,
Nakahara N, Tsuno T, Osawa H, Kuno T, Fujita M, Hatano M and
Yoshida J: Growth inhibition of human pancreatic cancer cells by
human interferon-beta gene combined with gemcitabine. Int J Mol
Med. 15:277–283. 2005.PubMed/NCBI
|
|
15
|
Detjen KM, Farwig K, Welzel M, Wiedenmann
B and Rosewicz S: Interferon gamma inhibits growth of human
pancreatic carcinoma cells via caspase-1 dependent induction of
apoptosis. Gut. 49:251–262. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Accolla RS, Scupoli MT, Cambiaggi C, Tosi
G and Sartoris S: Cell lineage-specific and developmental
stage-specific controls of MHC class-II-antigen expression. Int J
Cancer Suppl. 6:20–25. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garvie CW and Boss JM: Assembly of the RFX
complex on the MHCII promoter: Role of RFXAP and RFXB in relieving
autoinhibition of RFX5. Biochim Biophys Acta. 1779:797–804. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hanna S and Etzioni A: MHC class I and II
deficiencies. J Allergy Clin Immunol. 134:269–275. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Scupoli MT, Sartoris S, Tosi G, Ennas MG,
Nicolis M, Cestari T, Zamboni G, Martignoni G, Lemoine NR, Scarpa A
and Accolla RS: Expression of MHC class I and class II antigens in
pancreatic adenocarcinomas. Tissue Antigens. 48:301–311. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Surmann EM, Voigt AY, Michel S, Bauer K,
Reuschenbach M, Ferrone S, von Knebel Doeberitz M and Kloor M:
Association of high CD4-positive T cell infiltration with mutations
in HLA class II-regulatory genes in microsatellite-unstable
colorectal cancer. Cancer Immunol Immunother. 64:357–366. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Gaida MM, Welsch T, Herpel E,
Tschaharganeh DF, Fischer L, Schirmacher P, Hänsch GM and Bergmann
F: MHC class II expression in pancreatic tumors: A link to
intratumoral inflammation. Virchows Arch. 460:47–60. 2015.
View Article : Google Scholar
|
|
22
|
Park JK, Henry JC, Jiang J, Esau C, Gusev
Y, Lerner MR, Postier RG, Brackett DJ and Schmittgen TD: miR-132
and miR-212 are increased in pancreatic cancer and target the
retinoblastoma tumor suppressor. Biochem Biophys Res Commun.
406:518–523. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ma C, Nong K, Wu B, Dong B, Bai Y, Zhu H,
Wang W, Huang X, Yuan Z and Ai K: miR-212 promotes pancreatic
cancer cell growth and invasion by targeting the hedgehog signaling
pathway receptor patched-1. J Exp Clin Cancer Res. 33:542014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Ryan DP, Hong TS and Bardeesy N:
Pancreatic adenocarcinoma. N Engl J Med. 371:2140–2141. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Karakhanova S, Ryschich E, Mosl B, Harig
S, Jäger D, Schmidt J, Hartwig W, Werner J and Bazhin AV:
Prognostic and predictive value of immunological parameters for
chemoradioimmunotherapy in patients with pancreatic adenocarcinoma.
Br J Cancer. 112:1027–1036. 2015. View Article : Google Scholar : PubMed/NCBI
|
